496
Panorama Actual del Medicamento
REVISIÓN
Bibliografía
–
–
Arpa J, Enseñat A, García A, Gastón I, Guerrero A, Juan
FJ, Martínez ML, Montero C, Povedano M, Tranche S.
Guía para la atención de la esclerosis lateral amiotrófica (ELA)
en España. Ministerio de Sanidad y Política Social, 2009. Dis-
ponible en:
-
nesSanitarias/publicaciones/docs/esclerosisLA.pdf
–
–
Baldinger R, Katzberg HD, Weber M.
Treatment for
cramps in amyotrophic lateral sclerosis/motor neuron
disease.
Cochrane Database Syst Rev
. 2012 Apr 18;
4:
CD004157. doi: 10.1002/14651858.CD004157.pub2.
–
–
Beauverd M, Mitchell JD, Wokke JH, Borasio GD.
Re-
combinant human insulin-like growth factor I (rhIGF-I) for
the treatment of amyotrophic lateral sclerosis/motor neu-
ron disease.
Cochrane Database Syst Rev
. 2012 Nov 14;
11: CD002064. doi:10.1002/14651858.CD002064.pub3.
–
–
Bedlack RS, Pastula DM, Hawes J, Heydt D.
Open-label
pilot study of levetiracetam for cramps and spasticity in
patients with motor neuron disease.
Amyotroph Lateral
Scler
2009;
10
: 210-5.
–
–
Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna
K, McLaughlin R, Hardiman O.
Rate of familial amyo-
trophic lateral sclerosis: a systematic review and meta-
analysis.
J Neurol Neurosurg Psychiatry
. 2011; 82(6): 623-
7. doi: 10.1136/jnnp.2010.224501.
–
–
Díaz LM, Fernández del Pozo B, Martín L.
Enferme-
dades neurodegenerativas. En:
Principios de Fisiopato-
logía para la Atención Farmacéutica
. Módulo 4. Madrid:
Consejo General de Colegios Oficiales de Farmacéuticos;
2009. pp. 43-71.
–
–
EFNS Task Force on Diagnosis and Management
of Amyotrophic Lateral Sclerosis: Andersen PM,
Abrahams S, Borasio GD, de Carvalho M, Chio A,
Van Damme P, Hardiman O, Kollewe K, Morrison
KE, Petri S, Pradat PF, Silani V, Tomik B, Wasner M,
Weber M.
EFNS guidelines on the clinical management of
amyotrophic lateral sclerosis (MALS)--revised report of an
EFNS task force.
Eur J Neurol
. 2012;
19(3): 360-75. doi:
10.1111/j.1468-1331.2011.03501.x.
–
–
Leigh N, Wijesekera L.
Esclerosis lateral amiotrófica.
.
php?lng=ES&data_id=106&Disease_Disease_Search_
diseaseGroup=esclerosis-lateral-amiotrofica&Disease_
Disease_Search_diseaseType=Pat&Enfermedade(s)/
grupo%20de%20enfermedades=Esclerosis-lateral-amiotr-
fica&title=Esclerosis-lateral-amiotr-fica&search=Disease_
Search_Simple (actualización: mayo de 2011)
–
–
Malek AM, Barchowsky A, Bowser R, Youk A, Talbott
EO.
Pesticide exposure as a risk factor for amyotrophic la-
teral sclerosis: a meta-analysis of epidemiological studies:
pesticide exposure as a risk factor for ALS.
Environ Res
.
2012;
117
: 112-9. doi: 10.1016/j.envres.2012.06.007.
–
–
Miller RG, Mitchell JD, Moore DH.
Riluzole for amyotro-
phic lateral sclerosis (ALS)/motor neuron disease (MND).
Cochrane Database Syst Rev
. 2012 Mar 14; 3: CD001447.
doi: 10.1002/14651858.CD001447.pub3.
–
–
Mora JS (ed).
Esclerosis lateral amiotrófica. Una enferme-
dad tratable.
Prous Science
, 1999.
–
–
NEALS.
Biogen Announces Phase III Trial of Dexprami-
pexole Did Not Meet Endpoints.
-
tium.org/news_press_release_biogen.php. 3 enero 2013.
–
–
Pastula DM, Moore DH, Bedlack RS.
Creatine for amyo-
trophic lateral sclerosis/motor neuron disease.
Cochrane
Database Syst Rev
. 2012 Dec 12;
12: CD005225. doi:
10.1002/14651858.CD005225.pub3.
–
–
Qureshi MM, Cudkowicz ME, Zhang H, Raynor E.
Increased incidence of deep venous thrombosis in ALS.
Neurology
2007;
68: 76-7.
–
–
Robberecht W, Philips T.
The changing scene of amyo-
trophic lateral sclerosis.
Nat Rev Neurosci
. 2013;
14(4):
248-64. doi: 10.1038/nrn3430.
–
–
Spalloni A, Nutini M, Longone P.
Role of the N-methyl-
d-aspartate receptors complex in amyotrophic lateral scle-
rosis.
Biochim Biophys Acta
. 2013; 1832(2): 312-22. doi:
10.1016/j.bbadis.2012.11.013.
–
–
Turner MR, Hardiman O, Benatar M, Brooks BR, Chio
A, de Carvalho M, Ince PG, Lin C, Miller RG, Mitsu-
moto H, Nicholson G, Ravits J, Shaw PJ, Swash M,
Talbot K, Traynor BJ, Van den Berg LH, Veldink JH,
Vucic S, Kiernan MC.
Controversies and priorities in am-
yotrophic lateral sclerosis.
Lancet Neurol
. 2013;
12(3):
310-22. doi: 10.1016/S1474-4422(13)70036-X.
–
–
Wang H, O’Reilly ÉJ, Weisskopf MG, Logroscino
G, McCullough ML, Thun MJ, Schatzkin A, Kolonel
LN, Ascherio A.
Smoking and risk of amyotrophic late-
ral sclerosis: a pooled analysis of 5 prospective cohorts.
Arch Neurol
. 2011;
68(2): 207-13. doi: 10.1001/archneu-
rol.2010.367.
–
–
Wu CH, Fallini C, Ticozzi N, et al.
Mutations in the
profilin 1 gene cause familial amyotrophic lateral scle-
rosis.
Nature
. 2012;
488(7412): 499-503. doi: 10.1038/
nature11280.
Web de interés
–
–
ALS Therapy Development Institute.
/
–
–
ALS Worldwide.
/
–
–
Asociación Española de ELA (ADELA).
–
–
European Federation of Neurological Societies (EFNS).
/
–
–
EU Clinical Trials Register.
–
–
Federación Española de Enfermedades Neuromusculares.
–
–
Fundación Española para el Fomento de la Investigación en ELA (FUNDELA).
–
–
Fundación para la Investigación de la Esclerosis Lateral Amiotrófica.
–
–
Sociedad Española de Neurología.
